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ABSTRACT
Muscular Dystrophy (MD) is characterized by varying severity and time-of-onset
by individuals afflicted with the same forms of MD, a phenomenon that is not well
understood. MD affects 250,000 individuals in the United States and is characterized by
mutations in the dystroglycan complex. gmppb encodes an enzyme that glycosylates
dystroglycan, making it functionally active; thus, mutations in gmppb cause
dystroglycanopathic MD1. The zebrafish (Danio rerio) is a powerful vertebrate model for
musculoskeletal development and disease. Like human patients, gmppb mutant zebrafish
present both mild and severe phenotypes. In order to understand the molecular mechanisms
involved, we performed high-throughput RNA Sequencing (RNA-Seq) and small RNA
Sequencing at 4 and 7 days-post-fertilization (dpf) in mild and severe gmppb mutants and
controls. We hypothesize that variable phenotypes in gmppb mutants are due to differences
in gene regulation; therefore, we identified differentially expressed (DE) long non-coding
RNAs (lncRNAs) and microRNAs (miRNAs) - both potent genetic regulators. We
identified “MD-relevant” DE Ensembl-annotated genes involved in cell cycle regulation,
the immune response, neural development and maturation, and skeletal muscle atrophy.
We identified DE miRNAs that regulate these DE genes in the 4dpf severe mutants –
identifying 55 of these interactions. We utilized a novel method of visualizing gene
expression networks by generating co-expression networks of miRNAs and subsequently
removing miRNA nodes to identify important miRNAs. We identified 95 potential
lncRNAs for further analysis. By integrating analyses of both coding and non-coding
genes, we contributed towards the understanding of the molecular mechanisms of
Dystroglycanopathy, highlighting potential phenotypic modulators.
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1. INTRODUCTION

1.1 Muscular Dystrophy
Muscular Dystrophy (MD) is a group of debilitating musculoskeletal disorders that
affects 250,000 individuals in the United States1. At the moderate end, MD symptoms can
develop during late adulthood and be characterized by weak, but still functional muscles
(Appendix A, Table A1). At the more severe end of the spectrum, symptoms can develop
prenatally and consist of severe brain and eye abnormalities which often lead to miscarriage
of the developing fetus2. To some extent, symptoms are related to the form of MD an
individual has. There are nine main forms of MD (Appendix A, Table A1); each caused by
mutations in dozens of different genes encoding the protein subunits of the dystroglycan
complex, or in some cases, mutations in enzymes involved in post-transcriptional
modification of these subunits.
Mutations in any of the protein components of the dystroglycan complex can cause
MD (Figure 1). This complex is essential in skeletal muscle as it provides structural
stability to the sarcolemma by linking the cells to one another, resulting in long, robust
fibrils. The dystroglycan complex consists of the transmembrane β-dystroglycan complex
which is bound to ɑ-dystroglycan. On the intracellular end of β-dystroglycan, dystrophin
subunits polymerize and are eventually linked to the cytoskeleton. The sarcoglycans
provide increased stability to the complex and help mediate the strong connection between
ɑ and β dystroglycan3. ɑ-dystroglycan is a ligand for laminin 2 which links the complex to
the extracellular matrix. This interaction is crucial during muscle contraction, where
impediment of this complex leaves muscle fibers more susceptible to damage. Two of the
1

most common forms of MD, Becker MD (BMD) and Duchenne's MD (DMD) are caused
by mutations in dystrophin, the intracellular tether that links the dystroglycan complex to
the cytoskeleton. Generally, the more severe phenotype of DMD is attributed to genetic
mutations that results in premature termination of dystrophin whereas BMD is the result of
missense or frameshift mutations which do not majorly impact the length of the protein4–6.
As stated previously, mutations in any of these protein subunits can lead to MD; however,
mutations in genes associated with post-transcriptional modification of these subunits can
also cause MD.

Figure 1. The dystroglycan complex consists of multiple protein subunits that connect the
extracellular matrix to the cellular cytoskeleton. Figure taken from Barresi, 20182.
2

1.2 Dystroglycanopathies
Dystroglycanopathies include two forms of MD: Congenital MD (CMD) and Limb
Girdle MD (LGMD). They are caused by improper glycosylation of the protein subunits
composing the dystroglycan complex, a post-transcriptional modification. The ɑ and β
dystroglycan subunits are derived from the same gene - the transcribed dystroglycan
mRNA is split into two mRNAs prior to translation7. Mutations in dystroglycan lead to
decreased muscle fiber strength, similar to the result of mutations in dystrophin. Besides
being involved in muscle fiber strength, the α-dystroglycan subunit is also involved in
signaling pathways. Under certain conditions, it inhibits survival signaling in muscle cells
via caspase activation, leading to muscle cell apoptosis8, another characteristic result of
MD. In addition, the dystroglycan complex serves as a node in the signal transduction
pathway that leads to activation of STAT3 (signal transducer and activator of transcription
3). STAT3 plays an important role in regulating satellite cell self-renewal, and inducing
expression of Interleukin 6, a cytokine that acts as an anti-inflammatory myokine9. Thus,
improper formation of dystroglycan leads to multiple abnormal regulatory pathways. As
stated before, for dystroglycan to be functional, it must be glycosylated. There are 17 genes
many of which are enzymes that have been implicated in dystroglycan glycosylation (Table
1). Even within dystroglycanopathies, the symptom severity and time of onset varies
greatly - even within individuals with mutations in the same genes, a perplexity that is not
well understood2. This phenotypic complexity warrants further studies to understand the
genetic basis behind these differences.
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Table 1. Genes Associated with Dystroglycanopathic Muscular Dystrophy10.

1.3 Skeletal Muscle Structure
Skeletal muscle is one of the three major muscle types. It consists of striated muscle
tissue controlled voluntarily via the somatic nervous system. Skeletal muscle is attached to
bones via bundles of collagen and its rigidity comes from the fractal arrangement of
subunits (Figure 2). The muscle is composed of multiple muscle fascicles lined up in a
parallel fashion, wrapped in a connective tissue sheath called the epimysium, which is
surrounded by an outer connective tissue layer, called the fascia. The muscle fascicles are
composed of multiple muscle fibers surrounded by another connective sheath called the
perimysium; blood vessels and nerves are dispersed between the fascicles. The muscle
fibers are cylindrical, multinucleated cells, with a sarcolemma cell membrane that result
4

from fusion of multiple cells during myogenesis, or muscle development. The muscle
fibers are surrounded by another connective tissue layer called the endomysium. Muscle
fibers themselves consist of multiple myofibrils aligned in an organized parallel fashion
with abundant mitochondria dispersed throughout. The myofibrils are composed of
myofilaments, sarcomere-based structures composed of thin actin filaments and thick
myosin filaments that shrink for muscle contraction and stretch for muscle relaxation11,12.
Neuromuscular junctions (NMJ) are sites where a motor neuron meets a muscle fiber.
Excitation signals travel from the brain down the neuron to the muscle fiber. The muscle
fiber is surrounded by the sarcoplasmic reticulum, which upon exposure to acetylcholine
provided by the action potential, opens up sodium channels that allow for an influx of
sodium into the cell. This signal propagates, causing voltage sensitive calcium channels to
open, allowing for an influx of calcium into the myofilaments which allows myosin to
bring the actin filaments closer together via the sliding filament model, initiating muscle
contraction13.
Exercise and repeated use of muscles leads to structural changes in the muscle
fibers. Some of these changes include angiogenesis - formation of more extensive capillary
networks to meet the oxygen needs of the muscle, increased production of mitochondria,
hypertrophy - increasing the diameter of the muscle fibers, and changes in the proportions
of slow oxidative (SO), fast oxidative (FO), and fast glycolytic (FG) fibers14. Strenuous
exercise can cause muscle fiber damage via overstretching of sarcomeres, leading to
inflammation and damage to the connective tissue layers of the muscle. Overall, this leads
to necrosis, that peaks 48 hours after strenuous activity or overuse. Healthy exercising
persons undergo this process constantly and can regenerate the damaged muscle fibers

5

through satellite cell proliferation and differentiation. Satellite cells are found underneath
the basal lamina of muscle fibers15 and begin proliferating when exposed to signals derived
from damaged fibers and infiltrating immune cells. Following proliferation, they
differentiate into myoblasts which through fusion replace the damaged muscle fibers16.
Notch signaling is thought to play an important in role in stimulating this process17. In
individuals with Muscular Dystrophy, regeneration after muscle fiber damage is impeded
due to satellite cell depletion16.

Figure 2. Skeletal Muscle Structure12.
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1.4 Zebrafish as a model organism for Skeletal Muscle Development
The zebrafish (Danio rerio) is a well-established vertebrate model organism that
has been used to study neurological diseases including Alzheimer’s and Parkinson’s
disease as well as musculoskeletal disorders. Zebrafish development is much faster than in
mice models, and they are cheaper and require less physical space to grow. Zebrafish have
70% of genes conserved with humans18. Structurally, they have many of the same organs
and systems that humans have, including a heart, brain, spinal cord, various types of
musculature, blood, and both an innate and adaptive immune system. Several methods,
including CRISPR/Cas9, can be used to develop transgenic zebrafish where specific
mutations can be introduced.
Zebrafish skeletal muscle structure closely resembles that of humans, making them
good models for musculoskeletal development. Using zebrafish, precursors to slow and
fast twitch muscles have been identified and observed during development19. Additionally,
the interaction between the muscle fibers attachment to the cytoskeleton and the
extracellular matrix and how it relates to muscle rigidity has been determined20, and the
molecular mechanism of muscle cell contraction has been elucidated21. Of course, these
are but a few of the discoveries that zebrafish models of skeletal muscle development have
unraveled.

1.5 Zebrafish as a model organism for dystroglycanopathy
To better understand the complexity of dystroglycanopathy, accurate and useful
model organisms are required. Most models for MD are mice models. In fact, mouse
models of dystroglycanopathy exist that accurately represent the phenotypes of patients.
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These mutants have mutated genes earlier presented in Table 1 including large22, pomt123,
dag1

24

, and others. Unfortunately, similar zebrafish glycosylation mutants are still in

development; current mutants exist for ispd25, but most mutants are created transitively
using morpholino knockdowns. While morphants are useful in some contexts, the need
exists for stable zebrafish lines. A zebrafish model for Duchenne’s Muscular Dystrophy
(DMD) with mutated dystrophin exist which displays similar phenotypes as DMD human
patients, including myofiber atrophy, immune cell infiltration into skeletal muscle, and
abnormally shaped myofibrils20. Therefore, zebrafish have the potential to be an accurate,
convenient, and fast-growing model for dystroglycanopathy research. The Henry lab at the
University of Maine has been working on developing zebrafish with mutations in each of
the genes listed in Table 1.

1.6 A gmppb mutant model of dystroglycanopathy
One of the dystroglycanopathic zebrafish models that has been successfully
established by the Henry lab is a GDP-mannose Pyrophosphorylase (gmppb) mutant. The
protein product of gmppb catalyzes the conversion of mannose-1-phosphate and GTP to
GDP-mannose, a reaction involved in the production of N-linked oligosaccharides. These
sugars are produced in the Golgi Apparatus and then are subsequently attached to adystroglycan as a post-translational modification.

Mutations in gmppb have been

associated with Limb Girdle MD and Congenital MD due to hypo-glycosylated αdystroglycan26. As of 2018, 81 MD patients worldwide have been described with mutated
gmppb2,26–28. The low number of documented cases may be based on a lack of screening.
Astrea et al. tested this hypothesis, screening 73 Italian individuals with genetically
unidentified forms of Congenital MD and α-dystroglycan hypoglycosylation for gmppb
8

mutations2. Thirteen cases of gmppb biallelic mutations were identified in which seven
novel mutations in gmppb were revealed: all leading to highly variable phenotypes from
congenital clubfoot, seizures, neurodevelopmental abnormalities and autism spectrum
disorders2.
Zebrafish gmppb mutants were engineered by the Henry Lab using a CRISPR/Cas9
system previously described by Gagnon et. al29. Primers were designed using
CHOPCHOP29 with the intention of inserting a stop cassette in exon three of gmppb.
CRISPR/Cas9 was performed in one cell stage AB zebrafish embryos (F0 generation) and
the resulting fish were crossed to form the F1 generation which was similarly crossed to
form the F2 generation. Data presented in this thesis is from the F2 generation and
subsequent generations. Generation of the mutant line was done by the the Henry Lab30.
The Henry Lab’s gmppb mutant presents variable phenotypes, in a similar manner to
human patients with gmppb mutations. The mutants display muscular atrophy, decreased
muscle density, and disorganized muscle fibers (Figure 3), and can be classified by those
with either severe or mild phenotype.

Figure 3. Differences in severity of MD phenotypes in gmppb mutant zebrafish at two days
post-fertilization (2df). Control is gmppb wild type whereas mild and severe are
homozygous gmppb mutants. The bottom figure of each zebrafish shows the birefringence
which indicates skeletal muscle organization3. Figures courtesy of C. Henry lab.
9

1.7 Long non-coding RNAs
LncRNAs are regulatory genes located in regions of the genome previously termed
“junk DNA” that provide a novel lens to view physiological processes and diseases31.
These genes are transcribed into RNA, but not translated; thus, existing as RNA
intermediates that regulate gene expression through diverse, uncharacterized mechanisms
in both the nucleus and cytoplasm. For example, the lncRNA XIST directly interacts with
DNA, signaling the condensations of one of the X-chromosomes in mammalian females,
forming a barr body31. LncRNAs can also form secondary and tertiary structures that aid
in their mechanism of action. The lncRNA HOTAIR is a repressor of tumor repressor and
metastasis genes. It forms an intricate structure consisting of 56 helical segments, 38
terminal loops, 34 internal loops, and 19 junction regions32. LncRNAs are also able to
regulate gene expression by hybridizing with mRNA gene transcripts to signal mRNA
degradation, decreasing protein expression31. For example, the lncRNA α-HIF is a natural
antisense transcript of hypoxia-inducible factor 1 alpha (HIF-1α) that binds to HIF-1a
based on sequence similarity. When it does so, it exposes AU-riches elements present in
the 3’UTR of the HIF-1α mRNA, increasing the speed of mRNA degredation33. Alterations
in protein expression becomes much more complex when one considers the plethora of
interactions that a single protein can have, thus lncRNAs act as essential nodes in a complex
map of physiological processes. LncRNAs are considered the most functionally diverse
and numerous classes of RNAs34, yet their regulatory roles in the majority of processes and
diseases is not well understood. They even have proposed hypothetical roles in MD35, but
have yet to be experimentally investigated in this context.
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1.8 MicroRNAs
MicroRNAs (miRNAs) are another class of non-coding regulatory genes, who, in
contrast to lncRNAs, have well understood mechanisms of action. Additionally, miRNAa
are more conserved than lncRNAs with humans, and over 400 miRNAs are annotated by
Ensembl36 in the zebrafish. The biogenesis of miRNAs follows a conserved processing
pathway. Following transcription by RNA Polymerase II or III, the pri-miRNA is cleaved
by Drosha, a ribonuclease, to form a pre-miRNAs which is then able to exit the nucleus via
export by Exportin 5/RanGTP. Next, it is bound by Dicer, another ribonuclease, which
cleaves the hairpin structure such that the ~21 nucleotide fragment can be complexed with
Argonaut to form the RNA-induced silencing complex (RISC complex)37,38. Once the
complex is formed, miRNAs can post-transcriptionally modify gene expression through a
number of mechanisms. Based on the 4-9nt “seed sequence” of the miRNA complex,
complementary base-pairing of target mRNA transcripts can occur. This may lead to
cleavage of the target mRNA, poly-A-tail shortening, or blockage of the ribosome binding
site, preventing translation etc. In vertebrates, miRNAs primarily function by degrading
target mRNAs39. Currently, the specific role miRNAs play in MD is under-investigated.
MiR-188 has been identified as a biomarker of Duchenne’s MD, but it is unclear if this
miRNA might be contributing towards the phenotype40. Moreover, numerous miRNAs
have been shown to modulate apoptosis, regeneration, cell growth and organization:
processes that are likely pertinent to MD. Thus, investigating both miRNAs and lncRNAs
is a necessary step towards a better understanding of the genetic pathways involved in this
disease, and may have implications on the range of phenotypic severity and lifespan MD
patients display. By incorporating protein-coding gene expression, miRNA expression, and
11

lncRNA expression in genetic regulatory pathways, treatments could emerge that target
specific pathways to treat resulting symptoms, informing and advancing our understanding
of MD.

1.9 RNA sequencing to measure gene expression
RNA sequencing (RNA-Seq) is a high-throughput method to determine gene
expression. It can be used to identify differentially expressed genes, genes that are turned
on or off in certain situations and in response to stimuli, which can be used to answer
numerous research questions. RNA-Seq can also be used to examine alternative splicing
where exon usage may vary in different tissues or samples.
Illumina high-throughput RNA sequencing begins with isolation of RNA transcripts. Since
total RNA recovered using standard procedures contains >80% ribosomal RNA (rRNA)41,
standard protocol includes selection for poly-adenylated sequences using magnetic beads
or cellulose coated with oligo-dT molecules, a process that removes most of the rRNA.
Next, the transcripts are fragmented and converted to cDNA with ligated adapters used for
next generation sequencing (NGS). To ensure proper removal of rRNAs, rRNA depletion
is performed. Multiple strategies for rRNA depletion exist, but most utilize rRNA probes
that target rRNA transcripts, signaling them for degradation. For example, Roche’s KAPA
RNA HyperPrep Kit with Riboerase utilizes rRNA DNA probes that hybridize to rRNA
fragments, forming RNA-DNA hybrids, that are targeted by RNase H for degradation. This
method has less off-targets and preserves a higher proportion of non-coding RNAs than
other strategies for rRNA depletion42.
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Samples are then sequenced using Next Generation Sequencing (NGS). Following
this, a workflow is performed that utilizes multiple software to assemble and align reads,
annotate genes, and calculate gene expression. The output of sequencing is typically two
FASTQ files for each sequenced sample, one for forward reads and another for reverse
reads. First, these files are checked using FastQC43 which determines the read length and
quality. Next, the two FASTQ files are concatenated into one file, trimmed of the adapters
used for sequencing, and aligned to a given genome using either HISAT244 or BowTie45.
If one is interested in identifying novel transcripts, Stringtie46 is run to align the transcripts
to genes and identify ensembl-annotated genes. The bam file that is the result of BowTie
or HISAT2 is run through HTSeq247 which counts the number of transcripts that align to
each of the genes, and then DESeq248 can be used to identify differentially expressed genes.
Small RNA sequencing allows for the preferential sequencing of microRNAs (miRNAs).
It selects miRNAs using bead or gel-based size selection. Unlike most cellular RNAs,
mature miRNAs possess both a 3’ hydroxyl and a 5’ phosphate which allows for
preferential adapter ligation49. From there, cDNA preparation using reverse transcriptase,
sequencing, and transcript alignment and annotation occur as would in traditional RNA
Sequencing.
RNA Sequencing provides information about the expression of protein coding
genes which account for a mere 2% of the genome, as well as non-protein coding like long
non-coding RNAs (lncRNAs) and microRNAs (miRNAs). A relatively newer view of the
molecular mechanisms that lead to phenotype is that the way protein-coding gene are
regulated, where they are expressed and when, is just as important as the protein-coding
genes themselves. Therefore, traditional sequencing that excludes non-coding genes,
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potent genetic regulators of protein-coding genes, excludes a plethora of valuable
information. Non-coding regulatory genes are severely under investigated in MD, thus, we
aimed to emphasize them in our analysis.

1.10 MiRNA Network Attack
Co-expression networks are used to understand large genetic networks. In the
context of gene expression, they can be used to identify possible interactions between
genes. In these networks, the nodes represent individual genes, and edges between them
indicates that two genes are correlated – that their levels of expression are similar i.e. r2
>0.75). These co-expression networks can then be used for further analyses to identify gene
candidates.
Network attack models are a computational method of modeling a network’s
vulnerability in response to removal of nodes or edges. This is used for identification of
the most important edges or nodes, those that contribute most towards the network
stability50. They have been used to model social networks, identify key players in criminal
organizations51, and model power grids52, and have proposed benefits in modelling
relationships from large datasets generated from biological research50.
Network stability is defined by multiple parameters including the characteristic
path length, the degree of separation, and the network size. The characteristic path length
is the shortest path (the least number of edges) between two nodes. Nodes or edges that are
most important to the network stability, cause relatively large changes in the characteristic
path length upon removal. Another factor to consider in network attack graphs is the
degrees of separation. The value of the degrees of separation defines the number of nearly
independent networks, those with relatively few connections to other networks. An
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example of this could be the social activities of people worldwide. If the nodes were people,
and the edges were interactions, one would expect that each continent would have its own
relatively independent network that would consist of far fewer edges connecting nodes
between different continents than nodes within the same continent. Thus, the degree of
separation would be six, based on the number of inhabited continents. Moreover, if you
repeatedly selected edges that were transcontinental, after removing the last
transcontinental edge, a huge change in the characteristic path length would occur. The
network size is another useful parameter in finding important nodes. By repeatedly
removing nodes, large jumps in network size can be used to pinpoint nodes that contribute
to network stability.
Network attack has been used to model miRNA networks to compare miRNA
expression in different forms of cancer53. In the context of miRNA expression, nodes
represent individual miRNAs and edges connect the distinct miRNAs if they show similar
patterns of expression between different timepoints, treatments, etc. These co-expression
networks can identify miRNAs that are controlled by the same transcriptional pathway or
functionally related54. Furthermore, by attacking the network through removal of miRNAs,
nodes can be identified that cause large changes in characteristic path length or network
size. These nodes are thus important in maintaining the structure of the network and are
interesting candidates for further investigation.

1.11 MiRNA gene target analysis
MiRNAs recognize mRNA targets based on complementary base pairing of the
seed sequence of the miRNA with the mRNA transcript. TargetScanFish55 (version 6.2) is
a database with lists of zebrafish mRNAs targeted by zebrafish miRNAs that can be used
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in combination with differential gene expression to predict miRNA/mRNA relationships.
If a miRNA is differentially expressed and it is targeting a specific mRNA transcript, it
would be expected that the mRNA transcript would be differentially expressed in an
opposite direction of the miRNA, since most miRNAs cause degradation of their targets.
The relationship between miRNAs and their mRNA targets can be used to identify
upstream putative pathways that lead to biological differences.

1.12 Research Objectives
The primary goal of this research is to construct genetic regulatory networks that link
miRNAs, lncRNAs, and protein-coding genes to cellular processes implicated in
dystroglycanopathy phenotypes. We will do so with the following objectives:
1. Identify previously annotated lncRNAs and miRNAs that are differentially
expressed in the mutants.
a. Predict miRNA targets
2. Identify candidate novel lncRNAs via de-novo analysis from unannotated
transcripts that are differentially expressed in the gmppb mutants.
a. Characterize these lncRNAs and the adjacent genes to determine if they are
relevant to MD.
3. Incorporate lncRNA, miRNA, and protein-coding gene expression to construct a
genetic regulatory network that may contribute towards our understanding of the
molecular pathways involving MD phenotype.
4. Characterize the different types of mutations that were induced in the gmppb
mutants through Polymerase Chain Reaction (PCR) amplification of gmppb
mutants and subsequent sequencing.
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2. MATERIALS AND METHODS:

2.1 Overview of the experimental design
Four biological replicate samples of each treatment at each timepoint were
submitted for rRNA depletion, followed by small RNA sequencing and mRNA sequencing
(Figure 4). This included four samples of heterozygous gmppb mutants, four samples of
homozygous gmppb mutants that displayed mild phenotypes, and four samples of
homozygous gmppb mutants that displayed severe phenotypes. Each sample consisted of
total RNA made from homogenizing three embryos (as described in section 2.2). The two
timepoints included were 4 and 7 days post fertilization (dpf). For the small RNA
Sequencing, only 3 samples were submitted for each treatment due to insufficient total
RNA quantity.

Figure 4. Experimental overview of RNA Sequencing and small RNA Sequencing in
gmppb+/- controls and gmppb-/- mutants exhibiting mild or severe phenotypes.
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2.2 RNA extraction
Homozygous mutant and sibling control embryos were raised to the specified time
point (4 or 7 days post fertilization), and then the mutants were classified based on
birefringence using a confocal microscope in the Henry Lab. Birefringence was quantified
using FIJI as previously described20. Mutants with a percent area and a percent Mean Gray
Value at 85% or higher were classified as mild mutants; mutant embryos that did not meet
this standard were classified as severe30. Zebrafish were segregated into separate tubes
based on this classification system, euthanized via tricane, and preserved in 300 µL of trizol
by the Henry Lab following an approved University of Maine IACUC protocol. To obtain
sufficient RNA for RNA Sequencing, small RNA Sequencing, and quantitative Polymerase
Chain Reaction (qPCR), each sample consisted of 3 zebrafish embryos.
Samples were defrosted and homogenized using a Fisher PowerGen 125 (Fisher
Scientific, Waltham, MA) mechanical homogenizer. RNA Extraction was performed using
a Quick-RNA MicroPrep kit from Zymo following the manufactures protocol (Zymo
Research, Irvine, CA). Samples were centrifuged at 12,000xg for 1 minute and the
supernatant was removed and placed into a clean test tube. One volume ethanol (95-100%)
was added to each sample, mixed well, and then the mixture was transferred to a ZymoSpin IC column with a collection tube. The column was centrifuged 30 seconds at 12,000xg
and the flow through was discarded. The column was washed with 400 µL RNA Wash
Buffer, centrifuged for 30 seconds at 12,000xg, and flow through was discarded. A DNase
I Mastermix was prepared in an RNase free tube with 5 µL DNase I and 35 µL DNA
Digestion buffer per sample. The master mix was mixed via gentle inversion. Next, the
column was washed with 400 µL of RNA Prep Buffer followed by 700 µL RNA Wash
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Buffer, each time centrifuging for 30 seconds at 14,000xg and discarding the supernatant.
Next, the column was washed with 400 µL RNA Wash Buffer and centrifuged 2 minutes,
then placed into a new RNase free tube. 10 µL of DNase/RNase Free Water was added to
the center of the column and the sample was eluted via centrifugation for 30 seconds at
14,000xg. The eluted RNA quality and concentration was immediately read by a Thermo
Scientific NanoDrop OneC Spectrophotometer (Waltham, MA) and then samples were
stored in a -80C freezer. The Zymo protocol is available online at https://files.zymo
research.com/protocols/_r1050_r1051_quick-rna_microprep_kit.pdf.

2.3 RNA sequencing and small RNA Sequencing
Samples were submitted for RNA sequencing at QuickBiology in Pasadena,
California. Total RNA samples were assayed for quality using an Agilent Bioanalyzer 2100
(Agilent Technologies, San Francisco, CA) by QuickBiology.
Libraries for RNA-seq were prepared with a KAPA Stranded RNA-Seq Kit with a
RiboErase (KAPA Biosystems, Wilmington, MA) system. Final library quality and
quantity were analyzed by Agilent Bioanalyzer 2100 (Agilent Technologies, San
Francisco, CA) and Life Technologies Qubit 3.0 Fluorometer (Life Technologies,
Carlsbad, CA), respectively. The RNA Sequencing was performed on a HiSeq 4000
Illumina Sequencer (Illumina Inc, San Diego, CA) with 150 base paired end reads.
The same total RNA samples were submitted for small RNA Sequencing. The
library was prepared according to Qiagen QIAseq miRNA library kit (Qiagen Inc,
Germantown, MD) using 100 ng total RNA as input. Final library quality and quantity was
analyzed by Agilent Bioanalyzer 2100 and Life Technologies Qubit 3.0 Fluorometer. The
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Small RNA Sequencing was performed on an Illumina NextSeq 500 (Illumina Inc, San
Diego, CA) with 75 base paired end reads.

2.4 RNA sequencing annotation workflow
FastQC version 0.11.943 was used to verify the quality of the RNA Sequencing
reads prior to further analyses. All analyses were performed using Galaxy
(https://usegalaxy.org) and the histories of analyses be accessed through Galaxy upon
request.
Following FastQC diagnostic analyses, each of the FASTQ files were concatenated
tail-to-head to produce a single set of Forward (R1) and Reverse (R2) FASTQ files per
sample. FASTQ files were then trimmed using Trimmomatic version 0.38.056 which
removes the sequencing adapters, and low quality bases. The forward and reverse reads
were mapped to the GRCz11/danRer11 (May 2017) zebrafish genome assembly
(https://www.ncbi.nlm. nih.gov/assembly/ GCA_000002035.4/) using HISAT2 version
2.1.044. The resulting BAM (binary alignment and mapping) file for each sample was then
used to develop gene models using StringTie version 3.1.6 and the GRCz11 Ensembl
(version 98) GTF annotation file. The GTF file for each sample was combined using
StringTie Merge to produce a single GTF annotation file. A FASTA formatted sequence
file for each transcript in the GTF file was produced using GFFread from within Cufflinks
version 2.1.1.257. Next, the BAM files were run through HTSeq version 0.9.147 to count
the number of reads that map to exons of genes in the GTF annotation file. Read counts
per gene per sample were analyzed using DESeq2 version 2.11.40.648. Four different
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pairwise sample group comparisons were made to determine which genes were
differentially expressed. These comparisons included: 4dpf sibling vs. 4dpf mild, 4dpf
sibling vs. 4dpf severe, 7dpf sibling vs. 7dpf mild, and 7dpf sibling vs. 7dpf severe. For
each pairwise comparison, the normalized expression across all samples, log2 Fold Change
(log2FC), log ratio statistic, p-value, and false-discovery rate (FDR) adjusted p-value were
computed for each gene using DESeq2. After merging the DESeq2 files with the Ensembl
annotation, genes were subset based on gene type (i.e protein-coding, long non-coding
RNAs, miRNAs, etc.). Additionally, a script was run to annotate un-annotated transcripts
that were structurally similar to other annotated transcripts. Finally, GffCompare was used
to identify unannotated transcripts that were used for novel lncRNA identification.
Below is a pictorial example of this workflow using triplicate wildtype and
triplicate gmppb mutants (Figure 5).
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Figure 5. Gene annotation workflow for identifying differentially expressed ensembl annotated genes and unannotated novel
transcripts.

2.5 Small RNA sequencing workflow
Analysis of differentially expressed miRNAs was performed using miRExpress
version 2.058 using only the read 1 (R1) FASTQ files for each of the three biological
replicate samples profiled using small RNA sequencing. MiRExpress was used to trim
adapters and then align the trimmed reads to precursor miRNA sequences provided by
miRGeneDB version 2.059. The number of aligned reads to the 5p- or 3p-ends of the
precursor miRNA sequences were reported. These read counts for the mature miRNAs
were analyzed using DESeq2 to perform the same four pairwise comparisons done for the
RNA sequence described above.

2.5 Splicing analysis of gmppb mutants
To verify incorporation of the STOP cassette in the gmppb homozygous mutants,
gDNA hotshot extractions were performed based on the procedure described by Gagnon
et. al29. One 4dpf embryo was placed in a PCR tube per sample in non-lethal tricane. Once
the embryo appeared to be asleep, the liquid was removed and 20 µL of 50mM NaOH was
added. The sample was heated in a PCR machine for 20-30 minutes at 95C and then cooled
to 4C. 2 µL 1M TrisCl, Ph 8.0 was added and mixed via pipetting up and down. Samples
were frozen at 4C prior to Polymerase Chain Reactions.
To amplify the gmppb target region, PCR was performed with the reverse primer
(TGAAAGCTCTGATTCTTGTCGGTG) and the forward primer (CTGGTGGAACTTG
AGCATGTCGT). The genomic DNA was spun down on a bench top centrifuge and then
2 µL was added to each reaction tube in a 96 well PCR plate. To the reaction each of the
following were added: 1 µL of 20 uM primer (forward + reverse mixed), 0.125 µL Taq
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Polymerase (5000 Units/mL, New England Biological Laboratory, Ipswich, MA), 0.5 µL
of 10mM dNTPs, and 21.375 µL DI water -to bring the total volume to 25 µL. Samples
were quickly mixed via inversion, spun down, and placed in the PCR machine with the
following cycle temperatures and times:
Step 1: 95 degrees 3 minutes initial denaturing
Step 2: 95 degrees 20 seconds denature
Step 3: 60 degrees 25 seconds anneal
Step 4: 68 degrees 30 seconds extend
Step 5: Repeat steps 2-4 34 more times
Step 6: 68 for 5’ final extension
Step 7: Hold samples at 4C
The samples were submitted for sequencing at 10ng/mL and then the resulting
forward and reverse reads were aligned with wildtype gmppb and the STOP cassette using
Basic Local Alignment Search Tool (BLAST version 2.10.0)60. Mutants were categorized
based on the types of mutations that were present and the degree of and location of stop
cassette insertion. Mutated reads were analyzed using Open Reading Frame Finder (ORF
Finder) to validate whether stop codons were present in all possible reading frames. Finally,
the RNA Sequencing data was aligned based on the results and categorization of different
mutations found via qPCR analysis, to attempt to categorize the mutants based on their
gmppb mutations.
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2.6 Identification and characterization of differentially expressed novel and previously
annotated lncRNAs and nearby genes
Previously annotated differentially expressed lncRNAs were subset from the
annotated genes as described previously in section 2.4. Unannotated transcripts were also
subset as described in section 2.4. Fasta Sequences for each of the transcripts were
generated using GFFread57. To identify novel potential lncRNAs, the un-annotated
sequences were run through Coding Potential Assessment Tool (CPAT version 1.2.2)61 and
then RepeatMasker (version 4.1.0) to identify transcripts with high coding potential and
highly repetitive transcripts, respectively. A perl script was used to subset transcripts with
a coding potential less than 0.38. The RepeatMasker results were compiled to generate a
ratio of repetitive bases per transcripts (Appendix B, Section B.2), and transcripts were
subset based on a threshold of less than 50% repetitive bases.

2.7 Characterization of differentially expressed protein coding genes
Protein coding genes were subset from the annotated DESeq files generated in
section 2.4. Differentially expressed genes are defined as those with either adjusted or nonadjusted p-values less than 0.05. Information about each of the genes was gathered using
Ensembl

Biomart66,

including

the

gene

name

and

description.

Venny

2.0

(https://bioinfogp.cnb.csic.es/tools/venny/) was used to subset genes based on temporal
and sample dependent expression. Enriched gene sets with Gene Ontology annotations
were determined using David67,68 and Panther69. Additional functional information about
genes was obtained from GeneCards64 and AmiGO70,71.
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2.8 Characterization of differentially expressed miRNA and network attack
Differentially expressed miRNAs were subset from the small RNA Sequencing
data based on an adjusted p-value less than 0.05. An R script was generated to determine
the predominantly expressed miRNA based on expression, thus, the non-predominantly
expressed miRNA arm (otherwise known as the passenger strand) was discluded from
future analyses (Appendix B, section B.1). Venny 2.0 was used to look for trends in
expression across multiple samples and time points.
Network attack plots were generated using a combination of R and python scripts
to better understand the robustness of the networks present in the 4dpf/7dpf siblings,
4dpf/7dpf mild mutants, and 4dpf/7dpf severe mutants. Scripts to generate these plots can
be requested. Networks were imported into and visualized with Cytoscape version 3.7.272.

2.9 miRNA target analysis
MiRNA mRNA targets were identified from TargetScanFish55. The MirBase IDs
present in the TargetScanFish files were converted to MirGeneDB59 IDs using
MiRExpress58 which are the IDs present in the DESeq2 data. MiRNAs in the small RNA
Sequencing dataset that were differentially expressed at 4dpf in the severe mutants were
subset according to an adjusted P value < 0.05. Only the predominant strand of each
miRNA was included in the analyses, the passenger strand was excluded from the data.
Ensembl annotated genes from RNA sequencing that were differentially expressed at 4dpf
in the severe gmppb mutants according to an unadjusted p value < 0.05 were also subset.
These two lists were merged to look for differentially expressed miRNAs with
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differentially expressed mRNA targets. Finally, since miRNAs typically induce
degradation of their mRNA targets, miRNA and mRNA targets were subset based on an
opposite pattern of differential gene expression (i.e. miRNA was downregulated, and
mRNA was upregulated OR miRNA was upregulated, and mRNA was downregulated).
This data was used to generate networks in Cytoscape version 3.7.272.

2.10 Comparison of gene expression to cardiac regeneration
To highlight genes that might be involved in muscle-related phenotypes, proteincoding and miRNA gene expression was compared to that of a previous study exploring
differentially expressed genes involved in cardiac regeneration in zebrafish73. Venny 2.0
was used for comparison and gene ontologies for the protein-coding genes were determined
as described in section 2.7.
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3. RESULTS

3.1 mRNA sequencing of gmppb mutants

3.1.1 Identifying differentially expressed Ensembl annotated genes.
To identify potential gene candidates involved in modulating phenotypic severity,
differentially expressed gene transcripts were determined by comparing expression
between pairs of sample groups (Figure 6). The gene transcripts analyzed were those
annotated by Ensembl. As expected, using adjusted p-values, a more stringent significance
threshold decreases the number of genes defined as differentially expressed. At both
timepoints, severe mutants compared to sibling controls had a greater number of
differentially expressed genes relative to the mild mutants compared to sibling controls.
Next, a comparison of sets of differentially expressed genes from the four pairwise
comparisons was performed to determine the temporal and sample-specific expression of
the Ensembl annotated genes (Figure 7).

Figure 6. From mRNA sequencing, a list of differentially expressed gene transcripts
defined by a threshold of p<0.05, or adjusted p<0.05 were subset. Those with Ensembl
annotations are included in this figure. The table shows the number of differentially
expressed genes in each sample according to the threshold definition of differentially
expressed.
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Figure 7. Venn diagrams of differentially expressed Ensembl annotated genes. Panel A
includes genes with unadjusted p-values < 0.05 while panel B includes genes with
adjusted p-values < 0.05. Regions of overlap indicates genes that are differentially
expressed at the multiple specified timepoints or phenotypes. Percentages are included to
indicate the number of genes in each category over the total number of differentially
expressed genes.
Next, to characterize genes differentially expressed in the severe mutants at both
4dpf and 7dpf, Gene Ontology annotations were performed using PANTHER and DAVID.
Of the 82 differentially expressed genes (p-value < 0.05) common between 4dpf and 7dpf,
but not shared with 4dpf or 7dpf mild, only 47 were mapped to genes represented in
PANTHER or DAVID. Gene Ontology terms of interest included muscle organization,
extracellular matrix, cell adhesion, mitochondrial function, the immune system, and
transcriptional regulators (Tables 3 and 4).
The ten most differentially expressed Ensembl annotated genes were subset as
indicated by the largest positive or negative fold change (log2 FC) and an adjusted p-value
< 0.05. Eight of these genes came from the 7dpf severe mutants and two came from the
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4dpf severe mutants (Table 2). Three of these genes lack gene descriptions, and two of
them were not annotated as protein-coding genes.
It is important to note that in these analyses, all Ensembl genes, regardless of
whether they were protein-coding or not, were included. Therefore, non-coding genes,
including miRNA precursors and annotated lncRNAs, were present. Of the 881 total genes
differentially expressed across all pairwise comparisons, 22 were annotated as lncRNAs
and two as miRNA precursors. Of just the 82 genes differentially expressed in both the
severe mutants, one was annotated as a lncRNA and there were no annotated miRNA
precursors.
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si:ch211153b23.3

ENSDARG
00000104919

Protein coding

Antisense

CR354542.1
BX323064.2

Processed transcript

ano9a

ENSDARG
00000076320
ENSDARG
00000093922

ENSDARG
00000104365

anoctamin 9a

rprd2b

ENSDARG
00000074676

regulation of nuclear
domain containing 2b

pre-mRNA

CDC23 (cell division cycle 23, yeast,
homolog)
calcitonin/calcitonin-related
polypeptide, alpha

cdc23
calca

thioredoxin-like 1

txnl1

sema, transmembrane, and cytoplasmic
domain, semaphorin 6D, like

sema6dl

ENSDARG
00000011921
ENSDARG
00000044484
ENSDARG
00000056590

hydroxymethylbilane synthase a

hmbsa

ENSDARG
00000008840
ENSDARG
00000011533

Gene Description

Name

Gene ID

Table 2. Ten most differentially expressed Ensembl annotated genes.
7dpf Severe

61

32

55

873

4

31

84

1

124

2.81

0.75

0.10

-0.12

0.57

-2.02

-0.18

0.30

4.99

0.000

0.332

0.919

0.926

0.000

0.000

0.820

0.000

0.000

13

113

38

766

11

32

55

4

4

-1.23

-3.39

2.79

2.67

-2.67

3.78

2.77

-2.82

-0.97

2E-01

1E-36

8E-08

2E-08

4E-06

8E-13

4E-13

2E-04

3E-01

Base log2FC Adj P Base log2FC Adj P
202
-0.49 0.528
164
2.93 2E-08

4dpf Severe

Table 3. Differentially expressed (unadj p <0.05) genes with selected Gene Ontology
annotations at 4 and 7dpf in the severe mutants.
Gene ID

Name

Gene Description

4dpf Severe

Muscle Organization

7dpf Severe

Base

log2FC

P Val

Base

log2FC

P Val

ENSDARG
00000000563

ttn.1

titin, tandem duplicate
1

52

0.83

0.039

46

-0.98

0.042

ENSDARG
00000028213

ttn.2

titin, tandem duplicate
2

47

0.73

0.047

42

-0.92

0.030

ENSDARG
00000045302

smpx

small muscle protein Xlinked

124

-0.70

0.001

131

-0.41

0.027

ENSDARG
mmp9
00000042816
ENSDARG
fhod3b
00000061904
Cell Adhesion

matrix
metallopeptidase 9
formin homology 2
domain containing 3b

43

1.00

0.001

36

-0.85

0.008

24

-0.97

0.012

90

-2.56

0.000

ENSDARG
00000093008

adhesion G proteincoupled receptor F3b

13

-1.36

0.005

30

-0.87

0.024

ENSDARG
mmp9
00000042816
Mitochondrial Function

matrix
metallopeptidase 9

43

1.00

0.001

36

-0.85

0.008

ENSDARG
alas2
00000038643
ENSDARG
mt-nd6
00000063922
ENSDARG
lipt2
00000069852
Developmental Pathways

aminolevulinate, delta-,
synthase 2
NADH dehydrogenase
6, mitochondrial
lipoyl(octanoyl)
transferase 2

258

-1.62

0.001

733

-1.31

0.002

581

0.87

0.000

374

-0.55

0.041

75

0.58

0.013

70

-0.64

0.006

ENSDARG
00000074148

RAS
rbpjl

1073

0.53

0.001

587

1.81

0.000

ENSDARG
00000040959

NOTCH
rabl3

recombination signal
binding protein for ig
kappa J region
RAB, member of RAS
oncogene family-like 3

126

0.48

0.033

65

1.34

0.000

Extracellular Matrix

adgrf3b

Immune System

32

Table 3 Continued
Gene ID

Name

Gene Description

4dpf Severe

Transcriptional Regulation
ENSDARG
00000034300

sema3c

ENSDARG
00000035187
ENSDARG
00000036036
ENSDARG
00000038859
ENSDARG
00000040959
ENSDARG
00000053370

abl1

ENSDARG
00000055792
ENSDARG
00000056079

foxo4

ENSDARG
00000056590

calca

ENSDARG
00000071727
ENSDARG
00000074148

si:dkey37o8.1
rbpjl

ENSDARG
00000075670

rereb

ENSDARG
00000095332
ENSDARG
00000100536

si:dkey14d8.1
nkrf

mdka
rgs20
rabl3
eif3jb

l3mbtl2

7dpf Severe

Base

log2FC

P Val

Base

log2FC

P Val

93

-1.69

0.000

207

-0.87

0.000

111

0.39

0.042

102

-0.53

0.019

83

-0.57

0.015

98

-0.45

0.045

regulator of G protein
signaling 20
RAB, member of RAS
oncogene family-like 3
eukaryotic translation
initiation factor 3,
subunit Jb
forkhead box O4

191

-0.60

0.010

202

0.60

0.032

126

0.48

0.033

65

1.34

0.000

154

0.57

0.026

98

0.67

0.004

11

1.50

0.000

8

-0.89

0.047

L3MBTL
histone
methyl-lysine binding
protein 2
calcitonin/calcitoninrelated
polypeptide,
alpha
si:dkey-37o8.1

38

0.99

0.001

16

1.17

0.002

31

-2.02

0.000

32

3.78

0.000

196

-0.53

0.003

230

-0.34

0.041

1073

0.53

0.001

587

1.81

0.000

34

0.93

0.005

36

-1.26

0.000

28

0.81

0.023

22

-0.95

0.010

109

0.57

0.029

83

0.46

0.029

sema
domain,
immunoglobulin
domain
(Ig),
(semaphorin) 3C
c-abl oncogene 1, nonreceptor tyrosine kinase
midkine a

recombination signal
binding protein for ig
kappa J region
arginine-glutamic acid
dipeptide (RE) repeats
b
si:dkey-14d8.1
NFKB
factor

repressing

33

Table 4. Differentially expressed (adjusted p <0.05) genes with selected Gene Ontology
annotations at 4 and 7dpf in the severe mutants.
Gene ID
Name Gene
4dpf Severe
7dpf Severe
Description
Base

log2FC

Adj P

Base

log2FC

Adj P

ENSDARG
00000005941

clul1

clusterin-like
(retinal)

1

30

-2.13

0.000

121

0.25

0.000

ENSDARG
00000074148

RAS
rbpjl

107
3

0.53

0.020

587

0.23

0.000

ENSDARG
00000038643

alas2

recombination signal
binding protein for ig
kappa J region-like
aminolevulinate,
delta-, synthase 2

258

-1.62

0.028

733

0.41

0.020

ENSDARG
00000034300

sema3c

93

-1.69

0.000

207

0.25

0.008

ENSDARG
00000056079

l3mbtl2

38

0.99

0.018

16

0.38

0.026

ENSDARG
00000056590

calca

31

-2.02

0.000

32

0.48

0.000

ENSDARG
00000074148

rbpjl

sema domain, Ig,
secreted, semaphorin
3C
L3MBTL
histone
methyl-lysine
binding protein 2
calcitonin/calcitoninrelated polypeptide,
alpha
recombination signal
binding protein for ig
kappa J region-like

107
3

0.53

0.020

587

0.23

0.000
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3.1.2 Identifying novel transcripts for lncRNA analysis.
The ensembl annotated gene transcripts represented only a fraction of the total
differentially expressed genes in the gmppb mutants. It is likely that within this subset of
differentially expressed genes, previously unidentified lncRNAs exist. To identify
potential lncRNAs, a previously described workflow was used to subset novel transcripts
with low coding potential and low repetitiveness (Figure 8).

Figure 8. Identification of potential lncRNAs. A. Total genes (blue = ensembl annotated,
yellow = unannotated) with adjusted p-values less than 0.05 in 4dpf severe mutants. B.
Genes from panel A with Log2FC > 1 or < -1. C. Novel genes from panel B with Coding
Potential < 0.38 as determined by CPAT. D. Novel Genes from panel C with < 50%
repetitive bases.
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3.2 Small RNA sequencing of gmppb mutants to identify differentially expressed
miRNAs
Since standard mRNA sequencing selects for poly-adenylated transcripts, and
processed miRNA transcripts are not poly-adenylated, small RNA sequencing was
performed to measure processed miRNA expression74. In the dataset, there were a total of
265 miRNAs expressed across all samples. Figure 9 shows the number of differentially
expressed miRNAs in each sample; Figure 10 shows the overlap in differentially
expressed miRNAs between samples.

Figure 9. Number of differentially expressed miRNA as indicated by adjusted p-value <
0.05 and unadjusted p-values < 0.05.
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Figure 10. Overlap of differentially expressed miRNAs. A: miRNAs that are differentially
expressed according to an unadjusted p-value < 0.05. B: miRNAs that are differentially
expressed according to an adjusted p-value < 0.05. Venn diagrams made with Venny 2.0.
3.3 MiRNA co-expression networks
Co-expression networks can be used to identify sets of miRNAs that have
correlated expression patterns that can be used to infer common function. The topology
of these networks can be analyzed to determine nodes and edges that contribute towards
network stability. Number of miRNA nodes in each of the three co-expression networks
is listed in Table 5. Both characteristic path length and resultant network size are two
parameters used to identify important nodes (Figures M1 and M2). MiRNAs that, upon
removal, cause relatively large changes in characteristic path length are listed in Table 6.

Table 5. Number of nodes in miRNA co-expression networks.
Sample:
Number of Nodes
Sibling 4dpf and 7dpf
221
Mild 4dpf and 7dpf
255
Severe 4dpf and 7dpf
264
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Figure 11. Characteristic path length upon removal of individual nodes in miRNA
expression. miRNAs in each plot that upon removal cause relatively large changes in path
length are labeled. Resultant characteristic path length upon removal of miRNA nodes in
sibling 4dpf and 7dpf co-expression network (A), mild 4dpf and 7dpf co-expression
network (B), and severe 4dpf and 7dpf co-expression network (C). D has all three
networks overlaid into one graph.
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Table 6. miRNAs that upon removal cause gaps in characteristic path length
4dpf 7 dpf Sibling
4dpf 7dpf Mild
4dpf 7dpf Severe
Dre-Mir-204-P2a-5p
Dre-Mir_103-P3b-3p
Dre-Mir-17-P2a1-5p
Dre-Mir-15-P2a2-5p

Dre-Mir-126-P1-3p

Dre-Mir-132-p2a-5p

Dre-Mir-132-P1a-3p
Dre-Mir-130-P3b1-3p
Dre-Mir-103-P3a-3p
Dre-Let-7-P1b-5

Figure 12. Network size upon removal of nodes from sibling (black), mild (blue), and
severe (red) 4dpf and 7dpf co-expression networks.
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3.4 miRNA target prediction at 4dpf in the gmppb severe mutants
TargetScanFish was used to predict mRNA targets of miRNAs, and analyses were
performed to identify miRNA and mRNA targets with opposite expression at 4dpf in the
severe mutants. Only the predominantly expressed miRNAs were included in this
analysis. The first network with miRNAs upregulated and Ensembl annotated genes
consists of a total of 8 upregulated miRNAs and 13 downregulated Ensembl genes, for a
total of 37 interactions (Figure 13, Panel A). The second network has 7 downregulated
miRNAs and 9 upregulated Ensembl genes for a total of 18 interactions (Figure 14, Panel
B). Expression of each of the targeted genes is included in Tables 7 and 8.
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Figure 13. MiRNA and mRNA target interactions at 4dpf in gmppb severe mutants. A:
Each of the green nodes is an upregulated miRNA (unadjusted p <0.05); each of the red
nodes are downregulated ensembl annotated genes (adjusted p < 0.05). B: Green nodes
are upregulated ensembl annotated genes, red nodes are downregulated miRNAs. Edges
are denoted by arrows and show miRNAs targeting mRNAs based on TargetScanFish
data. The width of the edges is based on the context score of the interaction between the
miRNA and mRNA.
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Table 7. Upregulated mRNA targets of downregulated miRNAs in 4dpf Severe mutants.
Gene ID
Name
Gene Description
4dpf Severe
Base log2FC Adj P
ENSDARG0 sema6dl
Sema, transmembrane, 124
4.99 5.3E-41
0000011533
cytoplasmic
domain
semaphorin 6D like
ENSDARG0 cenpp
centromere protein P
134
0.56 4.0E-02
0000044135
ENSDARG0 CR628323.2 gap junction epsilon-1 84
0.73 2.0E-02
0000053062
protein-like
ENSDARG0 foxo4
forkhead box O4
11
1.50 8.3E-03
0000055792
ENSDARG0 c7b
complement component 23
1.63 9.6E-03
0000057121
7b
ENSDARG0 si:dkeysi:dkey-103g5.3
56
2.12 8.2E-08
0000062319 103g5.3
ENSDARG0 mmrn2b
multimerin 2b
261
0.82 4.8E-04
0000073711
ENSDARG0 mmrn2a
multimerin 2a
54
0.78 3.0E-02
0000076135
ENSDARG0 nudcd2
NudC domain containing 207
1.53 3.9E-10
0000078059
2

42

Table 8. Downregulated mRNA targets of upregulated miRNAs in 4dpf Severe mutants.
Gene ID
Name
Gene Description
4dpf Severe
Base log2FC Adj P
ENSDARG0 ptpn4b protein tyrosine phosphatase 461
-1.49 4.5E-07
0000000183
non-receptor type 4b
ENSDARG0 clul1
clusterin-like 1 (retinal)
30
-2.13 3.0E-04
0000005941
ENSDARG0 dnaaf1 dynein, axonemal, assembly 18
-1.21 1.3E-02
0000012030
factor 1
ENSDARG0 sema3c Sema and ig domain, 93
-1.69 2.2E-05
0000034300
secreted, (semaphorin) 3C
ENSDARG0 alas2
aminolevulinate,
delta-, 258
-1.62 2.8E-02
0000038643
synthase 2
ENSDARG0 fuom
fucose mutarotase
30
-1.15 2.0E-02
0000039422
ENSDARG0 smpx
small muscle protein X- 124
-0.70 3.1E-02
0000045302
linked
ENSDARG0 calca
calcitonin/calcitonin-related
31
-2.02 3.1E-05
0000056590
polypeptide, alpha
ENSDARG0 ino80
INO80 complex ATPase 459
-1.01 1.2E-02
0000070432
subunit
ENSDARG0 gabra5 gamma-aminobutyric acid 41
-0.93 1.6E-02
0000070730
(GABA) A receptor, alpha 5
ENSDARG0 dpy19l dpy-19
like
C- 313
-0.99 2.2E-05
0000079013 3
mannosyltransferase 3
ENSDARG0 ppp1r9 protein
phosphatase
1, 135
-0.71 5.9E-03
0000079366 ba
regulatory subunit 9Ba
ENSDARG0 sqlea
squalene epoxidase a
386
-0.71 9.2E-03
0000079946
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3.5 Splicing analysis of gmppb severe mutants
To produce a truncated gmppb protein product, a stop cassette was designed by
the Henry lab for incorporation into the early 5’ end of gmppb. The stop cassette had a
total length of 75 nucleotides with homology domains on either end, each 20 nucleotides
long; thus, the stop codons were from position 20-55. The left homology region was
homologous to intron 2 of gmppb and the right homology region was homologous to the
end of intron 2 and the beginning of exon 3 (Figure 14).

Figure 14. Stop cassette structure. The stop cassette consists of a left gmppb homology
domain and a right gmppb homology domain, with the stop codon region containing stop
codons in every reading frame. Shown in light blue is the where the regions of homology
share sequence with gmppb.

To verify incorporation of the stop cassette into the gmppb mutants, PCR and
sequencing of the gene gmppb was performed in 18 severe mutants. The mutants were
categorized based on the sequencing results. Two categories of mutations were found,
with one outlier. The first mutation, henceforth named the “partial double insertion”, was
present in 3 of the mutants. It consisted of insertion of one full stop region and one partial
stop region. In between the two stop cassettes was a right homology domain, and the left
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homology region was truncated, with only 6 of the 20 original nucleotides (Figure 15).
Notably, incorporation of this type of mutation resulted in a stop codon in every frame
which would be expected to yield a truncated gmppb protein product75.

Figure 15. Partial double insertion mutation structure. A. In three of the 18 sequenced
mutants, the stop cassette insertion consisted of incorporation of a partial stop cassette
followed by a full stop cassette. B. Shown is a simple pictorial representation of the
mutation with a subset of the left homology, a full stop cassette, a portion of the right
homology, a partial stop cassette, and then the right homology region.

A second category of mutations was characterized by a “TG Gap” and was present
in 14 of the 18 sequenced severe mutants (Figure 16). It was characterized by not only a
lack of stop cassette insertion, but a truncated left homology region where 8 nucleotides
were missing resulting in a truncated intron. ExpRESy indicated that stop codons were
present in five of the six possible reading frames.
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Figure 16. “TG Gap” mutation consists of an 8 base pair deletion between the left and
right homology domains of gmppb.

The findings from these analyses were next incorporated retroactively into the
previously collected RNA Sequencing data by searching for specific subsequences of
characteristic mutant regions in the FASTQ files. The queries “TAGTCTTACCTT” and
“AAGGTAACACTA” were used to identify reads that represented the double stop
cassette insertion mutation type in each of the samples (Figure QT) for both the forward
and reverse reads. To verify that these were from the correct region of the genome (i.e. to
confirm the were reads from gmppb), a secondary search was performed to determine the
subset of these reads that contained six nucleotides of exonic gmppb that based on a read
length of ~150nts should be present adjacent to the stop cassette (GGAGGC (e2) and
GTCCGT (e3)) To find reads that represented the “TG Gap”, the subsequences
“TGAACACCATTGGA” and “ACTTGTGGTAACCT” were searched for. In a similar
fashion as previously described, the reads were subsequently searched for sequences from
exon 2 and 3 of gmppb to verify that the reads were from the correct region (Figure 17).
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Figure 17. Characterization of reads from RNA Sequencing. The number of reads were
expressed as counts per million (CPM). A: Results from searching for
“TAGTGTTACCTT” and “AAGGTAACACTA”, sequences representing four
nucleotides of the right homology of the stop cassette (SC) and 4nts of the stop codons of
the SC to either end. B: Results from searching for an additional sequence in the resulting
reads from A, “GGAGGC” a sequence present in exon 2 of gmppb and “GTCCGT”, a
sequence present in exon 3 of gmppb. This step ensures that the reads come from gmppb.
C: In a similar fashion to graph A, a sequence, this time representing the TG Gap mutation
identified from the PCR of gmppb mutants, was searched for. D: Number reads with exons
2 and 3 subsequences.
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4. DISCUSSION & FUTURE DIRECTIONS
4.1 mRNA Sequencing of gmppb mutants

4.1.1 Differences in number of differentially expressed genes confirms differences in
gmppb mild and severe mutants.
Differentially expressed genes in the mild and severe mutants were identified using
adjusted and non-adjusted p-values to identify genes that contributed to phenotypic
severity. The shear difference in the number of differentially expressed genes correlates
with the Henry’s Lab method of distinguishing between the mild and severe mutants
(Figure 6). According to the unadjusted p-values, there are ~6 times more differentially
expressed genes in the severe mutants as opposed to the mild mutants at 7dpf; according
to the adjusted p-value, there are over 100 times more differentially expressed genes.
Another interesting trend is that there are ~6 times more differentially expressed genes in
the severe mutants at 7dpf as compared to the severe mutants at 4dpf. This could be due to
compounding effects from irregulated pathways at early time points, leading to cellular
responses aiming to restore the mutants to “normal” or “healthy” conditions. For example,
multiple pathways must be activated to restore the tissue damage, and likely many of these
are immune mediators. To better understand the gene pathways that contributed towards
the severe phenotype, genes differentially expressed in the severe 4dpf and 7dpf mutants,
but not the mild 4dpf and 7dpf mutants, were identified and further characterized.
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4.1.2 Gene Ontology characterization reveals phenotype-relevant genes.
Gene Ontology annotations for the genes differentially expressed in only the 4dpf
and 7dpf severe mutants were determined using PANTHER and DAVID. These databases
use manually curated and electronic annotations of Gene Ontology terms to characterize
genes from the zebrafish model organism database, ZFIN. When examining functional
annotation of genes, it is important to recognize that the zebrafish research community is
smaller than the mouse and human research communities and the number of annotations
are thereby smaller. Our entry list of 82 zebrafish genes resulted in a list of 47 genes with
annotations. PANTHER and DAVID list Gene Ontology annotations for the genes that
provide information about the biological processes, molecular function and cellular
components associated with the protein products of the genes. Because of the relatively
small number of input genes (82 for unadjusted p-values and 13 for adjusted p-values), the
only term that was enriched was “nucleus” with a p-value of 0.005. A list of MD relevant
terms that appeared in the PANTHER and DAVID annotations was selected and genes
were highlighted for further characterized based on these annotations. Terms included
muscle organization, extracellular matrix associated, cellular adhesion, immune function,
mitochondrial function, transcriptional regulators, and development pathways.
The immune response to skeletal muscle disorganization and destruction is an
important component of Muscular Dystrophy. Typically, following necrosis, the cellular
debris is removed by macrophages and muscle satellite cells (MuSCs) migrate to the site
of injury and proliferate to replace the lost tissue and restore muscle function. However, in
most forms of MD, the MuSCs are unable to properly restore muscle function, and instead
fibrotic tissue is deposited. The molecular mechanisms that modulate the immune response
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are best characterized in Duchenne’s Muscular Dystrophy (DMD)76. In DMD, dystrophic
muscle is invaded by CD4+ and CD8+ T cells, macrophages, eosinophils, and natural killer
cells77,78. Depletion of myeloid and lymphoid populations decreases myonecrosis

79–81

;

depletion of B and T cells reduced fibrosis and TGF-β1(15), and ablation of inflammatory
signals like IFNγ reduced the severity of muscle pathology82. Immunosuppressive
medications, like the glucocorticoid prednisone, has also been shown to improve muscle
strength in DMD patients and decrease myofiber injury83. However, the immune response
in MD is not strictly deleterious. For example, M2 macrophages are induced by Il-4 and
IL-13 to inhibit damaging inflammation and M1 macrophage mediated cytotoxicity84.
Thus, the immune response is an important and delicate component of the pathology of
MD and its role in dystroglycanopathy warrants further research.
Multiple immune relevant genes were differentially expressed in the severe
mutants. Of the 81 genes differentially expressed in both the 4dpf and 7dpf severe and not
the mild mutants, only one was related to the immune system: matrix metalloproteinase-9
(mmp9). MMPs have been shown to play an important role in myofiber functionality and
skeletal muscle cell migration, differentiation, and regeneration. One way they do so is by
degrading the extracellular matrix to allow for MuSC migration and differentiation to
replace lost tissue. Inhibition of MMPs suppresses migration of MuSCs to the site of injury
and impedes regeneration85,86. MMP-9 upregulation has been shown as a clinical biomarker
for Duchenne’s Muscular dystrophy87. In the severe mutants, at 4dpf, mmp9 was
upregulated, suggesting that the mutants were responding to the muscle damage by
promoting satellite cell migration and differentiation, but at 7dpf, it was downregulated,
suggesting a lack of response to damage (Table 3).
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Another interesting candidate that was differentially expressed in the 4dpf and 7dpf
with an adjusted p-value < 0.05 was clusterin-like-1 (clul1). The clusterin protein is a
molecular chaperone that inhibits apoptosis through stabilization of the Ku70-Bax protein
complex88. In the 4dpf severe mutants, clul1 was significantly downregulated,
corresponding to an increase in apoptosis according to the aforementioned pathway (Table
4). This could be a possible mechanism that results in myocyte death. However, apoptosis
is often a response, a last resort to other cellular damage – thus, we suggest that this is a
downstream effect of cellular damage in the MD mutants.
Genes were also ranked based on the ratio of expression as indicated by the fold
change (Log2 FC). The top 10 largest fold changes in expression were all in the severe
mutants, eight of these were from the 7dpf severe mutants and two were from the 4dpf
severe mutants. This is roughly the proportion we would expect based on the genes in each
category that were differentially expressed according to the adjusted p-value (67 genes in
the 4dpf severe and 338 genes in the 7dpf severe). Of the 10 most differentially expressed
genes, functions were related to cell growth, nervous system development, and muscle
contraction and relaxation.
Antomacin 9a (ano9a) is part of the antomacin family which encodes calciumchloride channels and it was differentially expressed in the 7dpf severe gmppb mutants.
There is little research characterizing ano9, however another member of this family is
implicated in MD. Antomacin 5 (ANO5) mutations are one of the causes of Limb-Girdle
MD. The protein product of this gene encodes a calcium-activated chloride channel that is
most abundant in the endoplasmic reticulum (ER) of skeletal muscle89. It is predicted to be
involved in regulating muscle contraction and relaxation. ANO5 also maintains calcium
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homeostasis which promotes plasma membrane repair in damaged myofibrils. Upon
deletion of ANO5 or pharmacological inhibition of injury-triggered calcium flow form the
ER to the cytoplasm, enabled injured patient myocytes to repair90. Although the specific
role of ano9 is unknown, based on the role of ANO5, it is an interesting candidate for future
research.
Cell division cycle 23 (cdc23) was upregulated in the 7dpf severe mutants. Cdc23
is a mitotic regulator that allows for cell cycle progression through the anaphase promoting
complex (APC). We predict that the upregulation of this gene is likely related to an
upregulation in cell division in an attempt to replace the lost myocytes. Interestingly, cdc23
was the only cell division cycle gene that was upregulated in the 4dpf or 7dpf mutants.
Finally, the sema family proteins were differentially expressed. Sema6dl was one of the
genes with the largest fold change. It was upregulated with a Log2FC of nearly 5.0. Sema3
was downregulated in both the 4 and 7dpf severe mutants. The sema receptors have been
implicated in multiple signaling pathways with roles in regulating innervation.
Specifically, sema3 has been shown to be involved in the innervation of skeletal muscle in
the diaphragm91 and sema2 loss-of-function mutants have ectopic innervation in the
muscle92. The loss of motor control in MD may be related to a lack of reinnervation or
improper reinnervation after myocyte damage. In MD in general, the Neuronal Muscular
Junctions (NMJ), the peripheral synapses that induce muscle contraction, are disorganized
– a phenotype shared in the gmppb mutants.
Interestingly, two of the most differentially expressed genes were not protein
coding – one was an antisense transcript and the other was a processed transcript, in the
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future we would like to look at these genes in more detail, as they could be unannotated
lncRNAs.
Of course, there are many different lenses to view the gene expression data and
identify candidates for future research. Another approach would be looking at genes that
are differentially expressed in both the mild and severe mutants - but have a higher
proportional change in expression in the severe as compared to the mild as indicated by the
Log2 FC.
Of the 881 annotated differentially expressed ensembl genes, 22 were annotated as
lncRNAs and two as miRNA precursors. In the past, we have found that the Ensembl
annotated lncRNAs tend to be highly repetitive – often exceeding 80% repetitive bases.
Thus, we would like to analyze these lncRNAs further and search for any functional
annotations in the literature in the future.

4.1.4 Identifying novel transcripts for lncRNA analysis.
To identify potential lncRNAs, novel transcripts were identified with low coding
potential and less than 50% of repetitive bases according to a previously described lncRNA
annotation workflow93. One thing that stands out in the 4dpf severe gmppb mutants is the
high proportion of differentially expressed unannotated, novel genes as compared to the
differentially expressed ensembl-annotated genes. In the past, this might have been
considered “transcriptional noise”94, but difficulty still persists in identifying transcripts
that are most likely to be related to the phenotype – and doing so requires extensive manual
analysis. To characterize these 98 potential lncRNAs, ORFFinder will be used to look for
open reading frames and BLAST will be used to identify transcripts with alignment to
known protein coding genes. Furthermore, these transcripts will be aligned to novel
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lncRNAs that were differentially expressed in caudal and cardiac regeneration in the
zebrafish to look for commonly differentially expressed transcripts. Additionally, the genes
to either side of the potential lncRNAs will be determined to indicate possible regulatory
targets since some lncRNAs act in a “cis” mechanism. Homologous lncRNAs in humans
will be identified. These analyses will be combined to generate a list of lncRNAs for qPCR
validation.

4.2 Small RNA sequencing of gmppb mutants to identify differentially
expressed miRNAs
To identify differentially expressed miRNAs, regulators of mRNA degradation,
small RNA Sequencing was performed. The number of differentially expressed miRNAs
according to an unadjusted p-value < 0.05 is similar in the 4dpf mild (55) and severe
mutants (63) (Figure 9). However, when you consider the differentially expressed miRNAs
according to the adjusted p-value, there were no differentially expressed miRNAs in the
mild mutants. We suspect that there were not any miRNAs with an adjusted p-value < 0.05
because we had only three biological replicates per sample group. Additional biological
replicates would need to be characterized in a future experiment to more accurately
characterize the biological variation in these sample groups. Since we only have three
biological replicates, an unadjusted p-value can be investigated further to reveal differences
in the phenotypic differences in the mild and severe mutants. In the analysis of the miRNAs
using unadjusted p-values, another trend was a lower number of differentially expressed
miRNAs in the 7dpf samples than in the 4dpf samples. This is contrasting to the trend
observed in the Ensembl annotated genes where there were more differentially expressed
genes in the 7dpf samples than in the 4dpf samples. Again, we suspect that this is a result
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of only 3 biological replicates characterized by small RNA Sequencing compared to 4
biological replicates for standard RNA sequencing.

4.3 MiRNA co-expression networks reveal miRNAs that contribute towards network
structural integrity.
Three gene co-expression networks were produced using 4dpf and 7dpf siblings,
4dpf and 7dpf mild gmppb mutants, and 4dpf and 7dpf severe gmppb mutants. Because we
filtered out lowly expressed miRNAs, the number of co-expressed miRNAs (nodes) in each
network was different. The number of nodes was lowest in the sibling network,
intermediate in the mild network, and highest in the severe network (Table 5). The sibling
showed the longest overall characteristic path length, the severe showed an intermediate
characteristic path length, and the mild displayed the shortest characteristic path length
(Figure M1). Network node attack analysis revealed multiple miRNAs that resulted in large
changes in the characteristic path length after they were removed from the network (Table
6). These miRNAs are candidates for further investigation. A shorter characteristic path
length implies biological networks working in conjunction and synergy74. Perhaps, the
additional stressor (the gmppb mutation), causes coordinated changes in miRNA
expression in an attempt to combat the dysregulated pathways and processes. It is possible
that the severe gmppb mutants have an intermediate characteristic path length because of
an inability to respond as effectively to the physiological changes induced by the gmppb
mutation. However, using this type of analysis in gene networks is a novel, thus, we need
to perform further research to determine how changes in network topology correlate with
genetic function.
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4.4 MiRNA target prediction at 4dpf in the gmppb severe mutants reveals an overlapping
network of miRNAs regulating a cohort of Ensembl annotated genes
By determining differentially expressed miRNAs with differentially expressed
Ensembl annotated mRNA targets with opposite expression, miRNA/mRNA interactions
can be predicted. In the 4dpf samples, a total of 55 such interactions were identified. The
gene targets of these interactions were further characterized in relation to functions and
processes implicated in the pathological progression of MD.
Four of the mRNA targets were previously identified based on the 10 most
differentially expressed analysis (calca) and differential expression (adj-p < 0.05) in the
severe mutants at 4dpf and 7dpf (clu1 (yes1), alas2, and sema3c). This analysis therefore
identified potential upstream regulators of potentially MD-relevant genes and pathways.
To identify mRNA/miRNA interactions of interest, Gene Ontology annotations of
the targeted mRNAs were analyzed, and a literature search was performed to identify
mRNAs with MD-relevant function. From this analysis, 8 genes of interest were identified
with functions related to cell growth regulation, immune activation, and neuron
transmission and function.
Cenpp and foxo4 are modulators of cell growth. Cenpp is a subunit of the CENPIassociated centromeric complex and is required for kinetochore function and miotic
progression96. In the severe 4dpf mutants, cenpp was upregulated - suggesting an increase
in cell division – likely in an attempt to replace the damaged tissue. Multiple downregulated
miRNAs are predicted to target cenpp, including dre-mir-31, dre-mir-155, and dre-mir34c. Forkhead box O transcription factors (foxo) are involved in cellular proliferation,
stress resistance, and apoptosis97. Overexpression of FOXO3 is linked to skeletal muscle
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atrophy through induction of atorign-1, a ubiquitin ligase98. Foxo4 is not well
characterized, but based on its inclusion in the foxo family, it could play a similar role in
inducing musclar atrophy. FOXO3 was significantly downregulated in the 4dpf severe
mutants – suggesting an increase in muscle atrophy. This gene was predicted to be targeted
by dre-mir-146a.
The protein complement 7b (c7b) is a component of the complement pathway of
the innate immune response that recruits the MAC attack complex to induce apoptosis of
target cells. C7b was upregulated, suggesting an increase in the innate immune response in
4dpf severe mutants that might contribute towards the loss of muscle mass in the mutants.
C7b was predicted to be targeted by dre-mir-205 and dre-mir-155.
The genes Protein Tyrosine Phosphatase Non-Receptor Type 4 (ptpn4b), GammaAminobutyric Acid Type A Receptor Subunit Alpha5 (gabra5), and Protein phosphatase
1, regulatory subunit 9Ba (ppp1r9ba) are involved in neuronal function and protection. In
the gmppb mutants, the neural muscular junctions (NMJs) are improperly formed and are
likely related to loss of motor control in the mutant zebrafish (Figure 3). Ptpn4b has been
shown to be involved in neural circuit formation in the brain of drosophila as it aids in
establishing and stabilizing axonal projection patterns99. Thus, ptpn4 inhibition causes an
increase in neuronal apoptosis100. In the 4dpf gmppb severe mutants at 4dpf severe, ptpn4b
was downregulated – suggesting a decrease in this process. Gabra5 encodes a subunit of
the GABA receptor, which is a ligand-gated chloride channel found in the brain. This
receptor’s ligand is GABA, an inhibitory neurotransmitter. Another symptom related to
MD is epilepsy which occurs in an estimated 6-7% of MD pediatric patients, as compared
to 0.5-1% in the general population101,102. Thus, this gene’s decreased expression in the
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4dpf severe mutants could be related to the loss of motor control inhibition in MD patients.
Ppp1r9b is a factor involved in promoting the formation of filopodia outgrows that can be
further remodeled to form dendritic spines that allow for excitation of neurons in the
brain103. Ppp1r9b was downregulated in the mutants, suggesting a decrease in formation
of filopodia outgrowths and a decrease in neural development and function. Ptpn4b,
gabra5, and ppp1r9ba were each predicted to be targeted by dre-mir-734. Ptpn4b and
gabra5 were predicted to be targeted by dre-mir-212, dre-mir-135, and dre-mir-489;
Ptpn4b was additionally predicted to be targeted by dre-mir-2187 and dre-mir-192.
Overall, this analysis was able to identify upstream regulators of protein-coding
genes with functions that appear to be related to the pathology of MD. To understand the
role of miRNAs in targeting mRNAs more thoroughly, these same interactions should be
identified in the other samples: 7dpf severe mutants, 4dpf mild mutants, and 7dpf mutants,
and the results should be compared.

4.5 Splicing analysis: gmppb severe mutants are characterized by two categories of
mutations
The splicing analysis revealed multiple types of mutations present in the severe
mutants, emphasizing the need to untangle how this might contribute towards the
phenotype severity. Interestingly, both types of mutations apparently resulted in the same
general phenotype, since all eighteen of the sequenced fish has severe phenotypes. This is
perhaps based on the observation that even with the “TG” gap mutation type, a substantial
deletion and frameshift mutation is induced that results in stop codons in five of the six
reading frames. However, for this to have any major impact on the length of the resultant
protein, the intronic region must be translated since the mutation occurs in the 3’ region of
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the intron. Perhaps, the mutation is disrupting the normal splicing of the mRNA which
leads to inclusion of the intron either resulting in a truncated protein via the included stop
codon or a dysfunctional protein based on the inclusion of the intron. Spliceosomes are
small nuclear ribonucleoproteins that carry out splicing. The vast majority of eukaryotic
introns are U2-type introns which are marked by a “GT” at the 5’ end and a “AG” at the 3’
end104. However, since the STOP cassette sequence contains multiple “GT” and “AT”
dinucleotides, predicting exactly how the mutations affect the splicing is difficult and
would be more accurately determined via functional studies, such as determining the
structure of the resulting protein.
Moreover, the presence of the different types of mutations in the fish is curious.
Why did some of them receive the double insertion while others have the “TG” gap? Some
of this might best be explained by scientific variability, whether it be in the fish themselves
or the handling of them. In respect to the “TG” gap, it is possible that homology directed
repair just never happened. After the cut was induced via the CRISPR/Cas9 system,
perhaps the stop cassette oligonucleotide was not proximal to the site so cut sequence was
eventually ligated back together after a few nucleotides were chewed off on either end.
Finally, of course when using a CRISPR/Cas9 system, the guide RNA must be
carefully and precisely designed to ensure the lowest possible chance of off-target affects.
ChopChop105, the tool that was used to generate the oligonucleotide sequences uses an
internal algorithm that rates the specificity of the sgRNA. Furthermore, to verify this, we
aligned the sgRNA sequence “GGACTCCAGCCTGAACACAG” against the GRCz11
zebrafish assembly using BLAT and only found one match – suggesting proper design of
the sgRNA. Thus, off-target affects are minimal.
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After all this, the characteristic mutation search results were our attempt to
incorporate our findings from the PCR into the previously collected RNA Sequencing data.
The goal was to determine if mutation types could explain the variability in phenotype in
the fish. What we found is that there only seems to be a small association with the stop
cassette mutation type in the 4dpf severe mutants. They appear to have a higher percentage
of “double partial insertions” and a lower percentage of “TG” gaps – suggesting that
perhaps the increase in severity (as compared to the mild mutants) is partially explained by
the different types of mutations. However, after searching for a short fragment of exon 2
or 3 in the reads matching the mutation types, this trend seems to disappear, making us
question whether or not the reads are from gmppb, or if they are in fact reads from a
different region of the genome. In order to investigate this, a more robust method of
validating the location of the reads would need to be used, likely with a method other than
grep. Furthermore, to really understand the effect of the DNA changes on the processed
mRNA transcript and subsequent translated amino acid sequence, a tool that can identify
intron/exon boundaries of zebrafish transcripts is needed. This would allow for prediction
of protein products which could be confirmed via protein isolation from mutants and amino
acid identification.
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APPENDIX A: COMPARISON OF MUSCULAR DYSTROPHY TYPES

Table A1. The nine main forms of MD106.
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APPENDIX B – SCRIPTS

B1 Identifying predominantly expressed miRNA
#Grace Smith. 1/16. This code will determine which miRNA end (5' or 3') is more highly
expressed
setwd("File/Path")
# Read in miRNA expression data
counts <- read.table("all_counts_normalized.txt",sep="\t",header=T)
counts[is.na(counts)] <- 0
#make lists of each of the arms
counts_5p <- counts[1,]
counts_3p <- counts[2,]
#add the rows based on the 2nd column containing either 3p or 5p
for (i in 3:550)
if (any(grepl("3p", counts[i,2])))
{ counts_3p <- rbind(counts_3p, counts[i,])
} else {
counts_5p <- rbind(counts_5p, counts[i,]) }
#write the tables
write.table(counts_3p, "3p_counts.txt", sep="/t")
write.table(counts_5p, "5p_counts.txt", sep="/t")
#change the column names of each
colnames(counts_5p) <- c("miRNA", "arm", "SIB4_5p", "MIL4_5p", "SEV4_5p",
"SIB7_5p", "MIL7_5p", "SEV7_5p")
colnames(counts_3p) <- c("miRNA", "arm", "SIB4_3p", "MIL4_3p", "SEV4_3p",
"SIB7_3p", "MIL7_3p", "SEV7_3p")
#now I want to compare the expression of the two arms
merged <- merge(counts_3p, counts_5p, by.x=1, by.y=1, all.x=TRUE, all.y=TRUE)
data <- merged[3:8]
data <- cbind(data, merged[10:15])
row.names(data) <- merged[,1]
data[is.na(data)] <- 0
avg <- data.frame(rowSums(data[1:6]))
avg <- cbind(avg, rowSums(data[7:12]))
row.names(avg) <- merged[,1]
colnames(avg) <- c("3p", "5p")
71

avg <- cbind(avg, (avg$`3p`-avg$`5p`))
#now, if 5p is higher, col3 = -; if 3p is higher col3 = +!!!!!
sum(avg[3]>0) #number 3p miRNAs that are expressed strand
sum(avg[3]<0) #number 5p miRNAs that are expressed strand
#now I want to write a file that only contains the predominantly expressed miRNAs and
not the passengers
predom_miRNA <- data.frame(merged[,1], stringsAsFactors=FALSE)
for (i in 1:287)
if (avg[i,3]>0) {
predom_miRNA[i,2] <- "3p"
} else {
predom_miRNA[i,2] <- "5p" }
colnames(predom_miRNA) <- c("miRNA", "arm")
p <- data.frame(predom_miRNA[,2])
row.names(p) <- predom_miRNA[,1]
write.table(p, "predominantly_expressed_miRNA_arm.txt", sep="")
#in excel I made a file that has the correct labels and then miRNAs with and without a *
at the end
a <- read.table("predominantly_expressed_miRNA_arm_passenger.txt", header=T)
b <- merge(a, counts[,2], by.x=1, by.y=1)
write.table(b, "labeled_predominantly_expressed_miRNA_arm.txt", row.names=F)
sum(grepl("\\*", b$predom_miRNA))
#tells you that 22 of the miRNAs that are predominantly expressed were labeled as
passengers!

B2 Repeat Masker analysis to identify candidate lncRNAs
#Grace Smith 1/23: Script reads in repeat masked files, calculates % repetitive bases
library(stringr)
setwd("Folder")
filenames <- list.files(pattern="masked.txt") #repeat masked files to read in
all_transcripts <- data.frame("ID", "total_bases", "repetitive_bases", "ratio_rep_bases")
colnames(all_transcripts) <- c("ID", "total_bases", "repetitive_bases", "ratio_rep_bases")
for (f in 1:length(filenames))
{
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b <- read.table(filenames[f], sep="\t", header=F)
A=N=0
for (i in 1:nrow(b))
{
if (grepl(">", b[i,1])) #means new transcript encountered
{
if (i==1 & f==1)
{
tran <- grep("MSTRG.\\d*.\\d*", b[i,1], value=T) #if 1st row & 1stfile, do
nothing
} else {
new <- data.frame(tran, A, N, (N/A))
colnames(new) <- c("ID", "total_bases", "repetitive_bases", "ratio_rep_bases")
all_transcripts <- rbind(new, all_transcripts)
tran <- grep("MSTRG.\\d*.\\d*", b[i,1], value=T) #get next id
A = N = 0 #reset parameters
}
} else {
A = A+str_count(b[i,1])
N = N+str_count(b[i,1], "N")
}
}
###if the end of file is reached, add the final row
new <- data.frame(tran, A, N, (N/A))
colnames(new) <- c("ID", "total_bases", "repetitive_bases", "ratio_rep_bases")
all_transcripts <- rbind(new, all_transcripts)
A=N=0
}
write.table(all_transcripts, "4dpf_Severe_ratio_repeat_masked_bases_adj_P.txt",
sep="\t")
Threshold <- 0.6
threshold_transcript <- subset(all_transcripts,
(all_transcripts$ratio_rep_bases<Threshold))
name <- paste(Threshold,
"Threshold_4dpf_Severe_ratio_repeat_masked_bases_adj_P.txt", sep="_")
write.table(threshold_transcript, name, sep="\t")
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